CannBioRex is developing newly patented compounds in orally active anti-inflammatories in a safe and effective way to fill several major unmet needs within:
CannBioRex’s Co-Founders Prof Sir Marc Feldmann and Prof Raphael Mechoulam are industry leading scientists who are experts in the development of anti-inflammatory therapeutics and are at the forefront of CannBioRex’s mission to develop safe medicines.
The Medical Marijuana industry is rapidly growing. Currently the market is valued at $14.3B USD. It is estimated to reach a market value of $74.3B USD by 2027 at a projected CAGR of 17.9% from 2017 to 2027. Marijuana has shown its benefits in multiple suppressive and therapeutic indications. Source: FULD+Company Analyst Report, Market and Competitive landscape for Medical Marijuana and synthetic cannabinoids Source: http://insights.fuld.com/blog/what-medical-marijuana-means-for-pharma-companies